Resources Repository
-
Resource PortalPublication, Teaching Resource 2017Immunization Financing: A Resource Guide
This resource guide compiles 26 briefs on topics related to the cost and financing of …
This resource guide compiles 26 briefs on topics related to the cost and financing of national immunization programs in low- and middle-income countries. The guide provides information and analysis to help advocates, policymakers, and program managers assess different financing options, approaches to strategic purchasing, and strategies for policy change, incorporating recent country experience in these areas. The guide is an update to the Immunization Financing Toolkit: A Resource for Policy-Makers and Program Managers, published by…
Priority Setting/Ethics | Costing Methods | Infectious Diseases | Health Systems | Global Governance | Economics/Finance | Health/Medicine | Science/Technology | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific | College | Graduate | Doctoral | Professional | Decision Making/Leadership | Policy Translation | Quantitative Literacy -
Resource PortalWeb Portal, Teaching Resource 2024MIDAS
MIDAS is a collaborative network of research scientists who use computational, statistical and mathematical models …
MIDAS is a collaborative network of research scientists who use computational, statistical and mathematical models to understand infectious disease dynamics and thereby assist the nation to prepare for, detect and respond to infectious disease threats. Midas focuses on research topics such as: Dynamics of emergence and spread of pathogens; Identification and surveillance of infectious diseases; Effectiveness and consequences of intervention strategies; Host/pathogen interactions; Ecological, climatic, economic and evolutionary dimensions of infectious diseases; The roles of behavior and behavioral adaptation in…
Cost-Effectiveness Analysis | Mathematical Models | Dynamic Transmission | Calibration/Validation | Dynamic Simulation | Risk Analysis | Technology Assessment | Infectious Diseases | Health Systems | Policy/Regulation | Climate/Environment | Health/Medicine | Science/Technology | Global | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Conceptual Mapping | Quantitative Literacy -
OrganizationWeb Portal 2024ISOQOL
The International Society for Quality of Life Research (ISOQOL), established in 1993, is a non-profit …
The International Society for Quality of Life Research (ISOQOL), established in 1993, is a non-profit society to advance the scientific study of health-related quality of life and other patient-centered outcomes to identify effective interventions, enhance the quality of health care and promote the health of populations. ISOQOL provides a networking opportunity for those in the quality of life research field. ISOQOL fosters exchange of information through: scientific publications, international conferences, educational short-courses and online webinars, and collaborative…
Preferences/Values | Health Outcomes | Health/Medicine | Global -
ArticlePublication 2016Country-Level Cost-Effectiveness Thresholds
This article estimates the cost-effectiveness thresholds (CETs) for health interventions in several low and middle-income …
This article estimates the cost-effectiveness thresholds (CETs) for health interventions in several low and middle-income countries (LMICs), based on opportunity costs. When there are constraints on a health care system’s budget or ability to increase expenditures, additional costs imposed by interventions have an “opportunity cost” in terms of the health foregone because other interventions cannot be provided. The authors argue that cost-effectiveness thresholds should reflect health opportunity cost and aim to calculate these in four…
Cost-Effectiveness Analysis | Priority Setting/Ethics | Health Systems | Economics/Finance | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Europe | Asia & Pacific -
ArticlePublication 2016Cost-Effectiveness of Routine Vaccination With a Live-Attenuated Dengue Vaccine: Model Comparison
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, …
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) over the first 25 months following vaccination. Subsequent data collected in the longer-term follow-up phase, however, have raised concerns about a potential increase in hospitalization risk of subsequent dengue infections, in particular among young, dengue-naïve vaccinees. This paper reports predictions from eight independent modelling groups on the long-term safety, public health impact, and cost-effectiveness of routine…
Cost-Effectiveness Analysis | Mathematical Models | Dynamic Transmission | Infectious Diseases | Child/Nutrition | Health Systems | Global Governance | Climate/Environment | Economics/Finance | Health/Medicine | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2016Cost-Effectiveness Thresholds: Pros and Cons
This WHO bulletin compares the two main methods for comparing the cost-effectiveness of health interventions. …
This WHO bulletin compares the two main methods for comparing the cost-effectiveness of health interventions. Cost-effectiveness thresholds allow health decision makers to identify cost-effectiveness ratios that represent good or bad value for money. In 2001, the World Health Organization's Commission on Macroeconomics in Health suggested cost-effectiveness thresholds based on multiples of a country's per-capita gross domestic product (GDP). In some contexts, these thresholds have been used as decision rules. However, this approach lacks country specificity…
Cost-Effectiveness Analysis | Priority Setting/Ethics | Health Systems | Health/Medicine -
ArticlePublication 2016Cost-Effectiveness of Hypertension Treatment According to 2014 Guidelines
This article compared the cost-effectiveness of hypertension treatment in non-Hispanic blacks and non-Hispanic whites according …
This article compared the cost-effectiveness of hypertension treatment in non-Hispanic blacks and non-Hispanic whites according to 2014 US hypertension treatment guidelines. The cardiovascular disease (CVD) policy model was used to simulate CVD events, quality-adjusted life years (QALYs), and treatment costs in 35- to 74-year-old adults with untreated hypertension. CVD incidence, mortality, and risk factor levels were obtained from cohort studies, hospital registries, vital statistics, and national surveys. The authors assumed a willingness-to-pay for health of…
Cost-Effectiveness Analysis | Microsimulation | Chronic Disease/Risk | Health/Medicine | North America -
ArticlePublication 2016Cost-Effectiveness of Intensive Blood Pressure Management
This article aimed to evaluate the cost-effectiveness of intensive blood pressure management compared with standard …
This article aimed to evaluate the cost-effectiveness of intensive blood pressure management compared with standard management among 68-year-old high-risk adults with hypertension but not diabetes. A Markov cohort model was developed to estimate lifetime costs and quality-adjusted life-years (QALYs) discounted at 3% annually. The Systolic Blood Pressure Intervention Trial (SPRINT) was used to estimate treatment effects and adverse event rates. The authors used Centers for Disease Control and Prevention Life Tables to project age- and…
Cost-Effectiveness Analysis | State-Transition | Chronic Disease/Risk | Health/Medicine | North America -
ArticlePublication 2016Cost-Effectiveness of Blood Pressure Treatment Guidelines in Adults 35-74
In this article the authors used the CVD Policy Model to compare the cost-effectiveness of …
In this article the authors used the CVD Policy Model to compare the cost-effectiveness of conservative versus intensive blood pressure treatment guidelines in adult hypertensive patients aged 35 to 74 years. Outcomes included in the study were CVD events, treatment costs, quality-adjusted life years, and drug and monitoring costs projected over the years 2016 to 2026. The effectiveness and costs of hypertension were calculated for treatment according to the 2003 Joint National Committee (JNC)-7 or…
Cost-Effectiveness Analysis | Microsimulation | Chronic Disease/Risk | Clinical Care | Health/Medicine | North America